Pseudomonas aeruginosa in German intensive care units

Abstract number: 1733_158

Meyer E., Schwab F., Gastmeier P., Rueden H., Jonas D.

Objective: To analyse resistance data of Pseudomonas aeruginosa (PAE) in German ICUs participating in the project SARI (Surveillance of Antimicrobial use and antimicrobial Resistance in German Intensive Care Units.)

Methods: From 2000–2005 resistance rates in 45 ICUs were calculated and correlated with antibiotic use and structure parameters. Temporal changes were tested by Wilcoxon test for paired samples.

Results: A total of 7187 PAE were included. The mean resistance rate to imipenem was 22.9% (range 0–50.4), to piperacillin-tazobactam 21 (range 0–50.4), to ceftazidime 16.1 (0–55.6), to ciprofloxacin 17.1 (range 0–50.4), to meropenem 13.8 (range 0–100). At 7% resistance to amicacin was lowest (range 0–68.6). Mean ceftazidime resistance increased significantly from 2000–2003 to 2004–2005 (from 14.6 to 18.8%) whereas amicacin resistance decreased from 8.2 to 4.5%. Ceftazidime resistance was significantly higher in hospitals with >1000 beds and resistance to amicacin was significantly higher in interdisciplinary ICUs. Carbapenem use correlated significantly and with a correlation coefficient >0.5 with imipenem, meropenem and ceftazidime resistance of PAE.

Conclusion: Over 20% of PAE in German ICUs are resistant to imipenem and piperacillin-tazobactam. This has not changed over the last 5 years. Carbapenem use and resistance correlate significantly.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Location: ICC, Munich, Germany
Presentation type:
Back to top